Business Standard

Sun Pharma rallies on FDA nod for cancer drug

USFDA have granted its subsidiary an approval for its ANDA for generic version of Doxil, Doxorubicin HCI liposome injection.

Related News

Sun Pharmaceutical Industries has rallied 4.4% to Rs 749 in morning trades after the company said US health regulators have approved a generic version of the drug Doxil.

“The U.S. Food and Drug Administration (USFDA) have granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) for generic version of Doxil, Doxorubicin HCI liposome injection,” said in a statement.

It will be available in 20 milligram and 50 milligram vials, it added.

Doxorubicin HCI liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.

The stock opened at Rs 735 and touched high of Rs 752 on the NSE. A combined around 960,000 shares have changed hands on the counter in early morning deals on both the exchanges.

 

Read more on:   
|
|

Read More

UCO Bank slips on declining net

Shares of UCO Bank has slumped after the bank posted a sharp drop in net profit for the third quarter ended December 31, 2012.

Quick Links

 

Market News

Higher open interest enthuses markets on expiry day

Rollover percentage in the Nifty was lower than three-month average, at 64%

Sensex scales record high; Nifty within kissing distance

Unperturbed by end of US Fed's bond buying, equities post healthy gains

BSE's entry into commex business to help revive investor confidence

Company can offer new and quality products learning from the mistakes of other commexes, says Finance Ministry official

Sensex hits fresh highs; TCS, Infosys up more than 2%

The Sensex has hit all time high of 27,359 levels whereas the Nifty is trading above 8,150

Mentha oil up 1% on spot demand

Oil for delivery in November edged up by 0.95%

Back to Top